🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Wow!! First Brazilian Oscar! 🇧🇷 For those who haven’t already, please watch this beautiful film! I’M STILL HERE is a brilliant movie about a real-life strong, resilient, and inspiring woman! So proud of our cinema! Vai Brasil!!🇧🇷💚💛💙

🚨🔥OncoAlert Hot off the press Just published The Lancet Results of #HARMONi2 phase 3 trial of #Ivonescimab (#PD1 & #VEGF Ab) vs #Pembrolizumab in pts with #PDL1+ advanced non-small cell #LungCancer in China. ⬆️#mPFS: 11.1 vs 5.8 months #HR: 0.51 👇🏻 thelancet.com/journals/lance…

🚨🔥OncoAlert Hot off the press Just published Nature Medicine Results of longitudinal analysis of #Molecular #Residual #Disease (#MRD) from #ADAURA phase 3 trial of adjuvant #Osimertinib in resected #EGFR+ stage IB–IIIA non-small-cell #LungCancer 👇🏻 nature.com/articles/s4159…

In the phase 2 DeLLphi-301 trial, tarlatamab showed durable responses in #SCLC, but adverse events management is critical. Revisit this important, #OpenAccess work: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… Jacob sands Suresh S. Ramalingam, MD, FASCO Taofeek K Owonikoko @pateloncology OncoAlert

🔥🚨OncoAlert Hot off the press. Just published Annals of Oncology In conjunction with presentation ESMO - Eur. Oncology #ELCC2025 Results of phase 3 trial of: #Subcutaneous Vs #IV #Pembrolizumab (+ #Chemo) in Metastatic Non–Small Cell #LungCancer #SQ (median admin time 2 minutes):

👉🏽Out in Journal of Clinical Oncology #Taletrectinib Next Gen TKI in ROS1+ Non–Small Cell Lung Cancer: #TRUST pooled analysis 🎯TKI-naïve/pretreated: ORR 88.8/55.8%, 🧠Intracranial-ORR 76.5/65.6%, mPFS 45.6/9.7mo ➡️AEs: LFT abnormalities, diarrhea, edema, less neuro AEs Maurice Perol Nathan A. Pennell MD, PhD, FASCO

1/2🔥🚨OncoAlert Hot off the press. Just published Springer Nature #CurrentOncologyReports by our team Mayo Clinic Comprehensive Cancer Center A #Review Article on: ✅The #Antibody-#Drug #Conjugates (#ADCs) Therapeutic 💊#Revolution in #LungCancer 🫁(#NSCLC & #SCLC). 👇🏻 link.springer.com/article/10.100…

🔥🚨OncoAlert Hot Off The Press. Just published NEJM Results of: ⭐️ #Beamion LUNG-1 phase 1a–1b of: #Zongertinib (#Oral, irreversible, HER2 #TKI) in previously treated #Patients with advanced #HER2-mutant non-small- cell #LungCancer (#NSCLC). 👇🏻 nejm.org/doi/full/10.10…

The best of the best! 🇧🇷🏎️🏁💚💛

1/3🧵 🔥Hot off the press. ⭐️My co-authors & I are excited to share this just published paper ASCO #ASCO25 #ASCOEdBook on a topic that is near & dear to my heart: ✅“The ART of #Oncology #Education & #Knowledge Sharing. It is All About the “#How” 👇🏻 ascopubs.org/doi/10.1200/ED…

🚨🔥OncoAlert Hot Off The Press 1/2 U.S. FDA granted #accelerated approval to #Telisotuzumab-Vedotin for: ⭐️ #Patients with advanced non-squamous non-small cell #LungCancer AND: ✅#High #cMet overexpression ✅Received a prior systemic therapy 👇🏻 fda.gov/drugs/resource…

Mayo Clinic Comprehensive Cancer Center will lead in more than 60 sessions at #ASCO25, including 59 Mayo Clinic-authored abstracts highlighting advancements in #CancerCare. These are some of the highlights you won't want to miss: newsnetwork.mayoclinic.org/discussion/may…

Honored and humbled to have finished a year with GRACE ! Thank you Amy Bickleman H. Jack West, MD, FASCO for all the support and learning! And thanks to my fellow friends and ambassadors Marie Dreyer Erick Saldanha, MD Maria Antonia Vélez Arya Roy

Thank you Rami Manochakian MD, FASCO Cancer Education for all the learning, and mentorship! Your support was essential for this project!

Thank you so much, Umair Majeed !

🔥🚨OncoAlert Hot off the press. Just published NEJM in conjunction with presentation ASCO #ASCO25 Results of #Challenge trial of: Structured #Exercise after adjuvant chemotherapy for #ColonCancer: ✅⬆️Disease-free survival ✅⬆️Overall survival 👇🏻 nejm.org/doi/full/10.10…